Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 414-418 , December 2009

Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy

Received 9 June 2009 ,Revised 29 September 2009 ,Accepted 11 October 2009.

References 

  1. Wright JL, et al. Clinical outcomes after reirradiation of paraspinal tumors. Am J Clin Oncol. 2006;29:495–502
  2. Joyner M, et al. Stereotactic body radiation therapy for centrally located lung lesions. Acta Oncol. 2006;45:802–807
  3. Onishi H, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2:S94–S100
  4. Timmerman R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124:1946–1955
  5. Nyman J, Johansson KA, Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer – mature results for medically inoperable patients. Lung Cancer. 2006;51:97–103
  6. Zimmermann FB, et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer. 2005;48:107–114
  7. Timmerman R, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4839
  8. Lovelock DM, et al. Accurate setup of paraspinal patients using a noninvasive patient immobilization cradle and portal imaging. Med Phys. 2005;32:2606–2614
  9. Spirou SV, Chui CS. A gradient inverse planning algorithm with dose–volume constraints. Med Phys. 1998;25:321–333
  10. Nicolini G, Fogliata A, Cozzi L. IMRT with the sliding window: comparison of the static and dynamic methods. Dosimetric and spectral analysis. Radiother Oncol. 2005;75:112–119
  11. National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0; 2003. Available from: http://ctep.cancer.gov/reporting.
  12. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75:677–682
  13. Hayakawa K, et al. Limited field irradiation for medically inoperable patients with peripheral stage I non-small cell lung cancer. Lung Cancer. 1999;26:137–142
  14. Jackson A, Yorke ED, Rosenzweig KE. The atlas of complication incidence: a proposal for a new standard for reporting the results of radiotherapy protocols. Semin Radiat Oncol. 2006;16:260–268
  15. Yamashita H, et al. Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol. 2007;2:21
  16. Baumann P, et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer – a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol. 2008;88:359–367
  17. Kopek N, et al. Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. Radiother Oncol. 2009;

PII: S0167-8140(09)00611-2

doi: 10.1016/j.radonc.2009.10.017

Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 414-418 , December 2009

Article Tools

* Image Usage & Resolution